BHA FPX 4020 Assessment 1 Health Care Problem Analysis Proposal

• BHA FPX 4020 Assessment 1 

Health Care Problem Analysis Proposal

Introduction to Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD) is one of the most significant public health challenges faced globally. Its prevalence cuts across all demographic groups, causing profound effects on individuals, families, and communities. Despite its widespread impact, mental health systems often lack adequate resources to address the issue effectively (World Health Organization, 2019).

This proposal focuses on shedding light on the underlying factors contributing to mental health problems, particularly MDD, and proposes evidence-based strategies to improve mental health outcomes. The increasing societal and economic burden of MDD emphasizes the urgency for action to alleviate its impact on global healthcare systems.

The World Health Organization (WHO) highlights that one in four people will experience a mental health condition during their lifetime. However, mental health complications are often sidelined in healthcare priorities, exacerbating the challenges of managing and treating these conditions effectively.

Problem Identification: Major Depressive Disorder (MDD)

Understanding Major Depressive Disorder

MDD is characterised by persistent feelings of sadness, hopelessness, and a loss of interest in previously enjoyed activities. This condition significantly impacts individual well-being and considerably burdens healthcare systems and society.

The selection of MDD as the focus of this analysis is rooted in its relevance and urgency. It is a pervasive mental health condition with profound personal and societal consequences. Addressing MDD requires tackling its root causes, enhancing mental health awareness, and providing evidence-based interventions.

The Broader Impact of MDD

Globally, MDD is the leading cause of disability, affecting over 264 million people (WHO, 2020). Beyond the illness itself, MDD often leads to comorbid conditions such as substance abuse, chronic disorders, and an increased risk of suicide (Kessler et al., 2019). These factors amplify the overall burden on individuals and public health systems.

Effective treatment of MDD aligns with broader public health goals, including reducing health disparities and improving population well-being. Evidence-based interventions for MDD can lead to better functionality, higher quality of life, and reduced healthcare costs.

Assessment and Measurement of Mental Health Disorders

Diagnostic Criteria

Diagnosis of MDD relies on the presence of specific symptoms outlined in the DSM-5, including:

• Depressed mood or anhedonia
• Altered appetite or weight
• Sleep disturbances
• Fatigue or low-energy
• Feelings of worthlessness or excessive guilt
• Difficulty concentrating
• Recurrent thoughts of death or suicide

Symptom Severity Assessment

Tools such as the PHQ-9 are widely used to measure the severity of depressive symptoms. This questionnaire evaluates symptoms over the past two weeks, providing a score that helps clinicians tailor treatment plans effectively.

Risk Assessment and Treatment Monitoring

Suicide risk evaluation is a critical component of MDD assessment. Clinicians utilise tools like the Columbia-Suicide Severity Rating Scale (C-SSRS) to assess suicidal ideation and behaviour. Additionally, scales like the QIDS monitor treatment progress and symptom changes.

Evidence-Based Solutions for MDD

Cognitive-Behavioral Therapy (CBT)

CBT is one of the most effective treatments for MDD, helping patients identify and modify negative thought patterns. Studies, such as those by Cuijpers et al. (2019), demonstrate its effectiveness in reducing depressive symptoms compared to control groups.

Mindfulness-Based Cognitive Therapy (MBCT)

MBCT integrates mindfulness practices with CBT principles, offering a valuable approach to preventing relapse in individuals with recurrent depression (Kuyken et al., 2020). Incorporating MBCT into treatment plans equips patients with tools to manage residual symptoms and sustain long-term recovery.

Industry Measures of Performance

Measuring Treatment Effectiveness

Performance standards for MDD treatment include symptom reduction and improved patient outcomes. Tools like the PHQ-9 and Beck Depression Inventory (BDI-II) are commonly used to evaluate the success of therapeutic interventions. A meta-analysis by Cuijpers et al. (2019) confirmed the effectiveness of evidence-based therapies such as CBT and IPT in reducing depressive symptoms.

Evidence-Based Psychotherapy

Evidence-based psychotherapy remains the cornerstone of effective MDD treatment. Healthcare organisations can benchmark their performance by tracking symptom severity reductions and patient satisfaction levels.

Preliminary Action Plan Steps

1. Conduct Comprehensive Research: Gather data on the prevalence, treatment options, and outcomes of MDD.
2. Engage Stakeholders: Include healthcare providers, patients, caregivers, and advocacy groups in the planning process.
3. Evaluate Resources: Assess available staff, funding, and infrastructure for implementing MDD interventions.
4. Form a Multidisciplinary Team: Collaborate with mental health specialists, researchers, and community members to develop actionable strategies.

Conclusion

This BHA FPX 4020 Assessment 1 proposal underscores the importance of addressing Major Depressive Disorder (MDD) within healthcare systems. As one of the most pervasive mental health challenges, MDD demands a comprehensive, evidence-based approach to reduce its impact on individuals and society.

This proposal aims to improve outcomes for those affected by MDD by identifying contributing factors, evaluating current treatment models, and implementing integrated care strategies. Strengthening mental health care frameworks will ultimately lead to enhanced quality of life and a reduction in the economic burden associated with this condition.

References

Bot, M., Brouwer, I. A., Roca, M., Kohls, E., Penninx, B. W. J. H., Watkins, E., van Grootheest, G., Cabout, M., Hegerl, U., Gili, M., Owens, M., & Visser, M. (2019). Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms. Journal of the American Medical Association (JAMA), 321(9), 858.

https://doi.org/10.1001/jama.2019.0556 

Gray, J. P., Müller, V. I., Eickhoff, S. B., & Fox, P. T. (2020). Multimodal abnormalities of brain structure and function in major depressive disorder: A meta-analysis of neuroimaging studies. American Journal of Psychiatry, 177(5), 422–434.

https://doi.org/10.1176/appi.ajp.2019.19050560 

Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Simes, M., Berman, R., Koenigsberg, S. H., & Kessler, R. C. (2021). The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics, 39(6).

https://doi.org/10.1007/s40273-021-01019-4 

Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., Paul, S. M., Jonas, J., Doherty, J. J., & Kanes, S. J. (2019). Trial of SAGE-217 in patients with major depressive disorder. New England Journal of Medicine, 381(10), 903–911.

https://doi.org/10.1056/nejmoa1815981 

Kennis, M., Gerritsen, L., van Dalen, M., Williams, A., Cuijpers, P., & Bockting, C. (2019). Prospective biomarkers of major depressive disorder: A systematic review and meta-analysis. Molecular Psychiatry, 25(2), 321–338.

https://doi.org/10.1038/s41380-019-0585-z 

Shin, C., Lee, S.-H., Han, K.-M., Yoon, H.-K., & Han, C. (2019). Comparison of the usefulness of the PHQ-8 and PHQ-9 for screening for major depressive disorder: Analysis of psychiatric outpatient data. Psychiatry Investigation, 16(4), 300–305.

https://doi.org/10.30773/pi.2019.02.01 

Widge, A. S., Bilge, M. T., Montana, R., Chang, W., Rodriguez, C. I., Deckersbach, T., Carpenter, L. L., Kalin, N. H., & Nemeroff, C. B. (2019). Electroencephalographic biomarkers for treatment response prediction in major depressive illness: A meta-analysis. American Journal of Psychiatry, 176(1), 44–56.

https://doi.org/10.1176/appi.ajp.2018.17121358